MA50501A - Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation - Google Patents
Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisationInfo
- Publication number
- MA50501A MA50501A MA050501A MA50501A MA50501A MA 50501 A MA50501 A MA 50501A MA 050501 A MA050501 A MA 050501A MA 50501 A MA50501 A MA 50501A MA 50501 A MA50501 A MA 50501A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- combination
- programmed death
- stable formulations
- ctla4 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762500268P | 2017-05-02 | 2017-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50501A true MA50501A (fr) | 2020-09-09 |
Family
ID=64016829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050501A MA50501A (fr) | 2017-05-02 | 2018-05-01 | Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation |
Country Status (16)
Country | Link |
---|---|
US (1) | US20200262922A1 (fr) |
EP (1) | EP3618866A4 (fr) |
JP (2) | JP2020518598A (fr) |
KR (1) | KR102624564B1 (fr) |
CN (1) | CN110678199A (fr) |
AU (1) | AU2018263837A1 (fr) |
BR (1) | BR112019022695A2 (fr) |
CA (1) | CA3060695A1 (fr) |
CL (1) | CL2019003143A1 (fr) |
CO (1) | CO2019012143A2 (fr) |
EA (1) | EA201992526A1 (fr) |
MA (1) | MA50501A (fr) |
MX (1) | MX2019013034A (fr) |
SG (1) | SG11201910134SA (fr) |
TN (1) | TN2019000294A1 (fr) |
WO (1) | WO2018204343A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100054780A (ko) | 2007-06-18 | 2010-05-25 | 엔.브이.오가논 | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
LT3551660T (lt) | 2016-12-07 | 2023-12-27 | Agenus Inc. | Antikūnai prieš ctla-4 ir jų naudojimo būdai |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
AU2019222517A1 (en) * | 2018-02-13 | 2020-08-13 | Merck Sharp & Dohme Llc | Methods for treating cancer with anti PD-1 antibodies and anti CTLA4 antibodies |
US20210380694A1 (en) * | 2018-11-07 | 2021-12-09 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
WO2020162203A1 (fr) * | 2019-02-08 | 2020-08-13 | 国立大学法人東京工業大学 | Mutant enzymatique pour méthode d'immunoessai homogène |
US20240115701A1 (en) * | 2019-09-23 | 2024-04-11 | Merck Sharp & Dohme Corp. | Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability |
US20230118596A1 (en) * | 2020-03-05 | 2023-04-20 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof |
US20220031843A1 (en) * | 2020-07-08 | 2022-02-03 | Regeneron Pharmaceuticals, Inc. | Stabilized Formulations Containing Anti-CTLA-4 Antibodies |
TW202235108A (zh) * | 2020-11-10 | 2022-09-16 | 法商賽諾菲公司 | Ceacam5抗體-藥物接合物配製物 |
US12110330B2 (en) | 2021-01-29 | 2024-10-08 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof |
WO2023211868A1 (fr) * | 2022-04-29 | 2023-11-02 | Merck Sharp & Dohme Llc | Formulations stables d'anticorps anti-ilt4 ou de fragments de liaison à l'antigène de ceux-ci en combinaison avec des anticorps anti-pd-1 et leurs procédés d'utilisation |
WO2024025989A1 (fr) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Compositions pharmaceutiques d'anticorps de récepteur de mort programmée 1 (pd-1) et rhuph20 ou variants ou fragments de ceux-ci |
WO2024025986A1 (fr) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Compositions pharmaceutiques d'anticorps de récepteur 1 de mort programmée (pd-1) et de variants de ph20 ou de fragments de ceux-ci |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103861102A (zh) * | 2005-03-08 | 2014-06-18 | 辉瑞产品公司 | 抗ctla-4 抗体组合物 |
NZ563193A (en) * | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
MX2011013722A (es) * | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
EA201792273A1 (ru) * | 2015-04-17 | 2018-04-30 | Бристол-Маерс Сквибб Компани | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела |
US9995753B2 (en) * | 2015-09-25 | 2018-06-12 | Merck Sharp & Dohme Corp. | Anti-pembrolizumab antibodies |
-
2018
- 2018-05-01 WO PCT/US2018/030420 patent/WO2018204343A1/fr active Application Filing
- 2018-05-01 CA CA3060695A patent/CA3060695A1/fr active Pending
- 2018-05-01 KR KR1020197035373A patent/KR102624564B1/ko active IP Right Grant
- 2018-05-01 TN TNP/2019/000294A patent/TN2019000294A1/en unknown
- 2018-05-01 CN CN201880029175.1A patent/CN110678199A/zh active Pending
- 2018-05-01 AU AU2018263837A patent/AU2018263837A1/en active Pending
- 2018-05-01 EA EA201992526A patent/EA201992526A1/ru unknown
- 2018-05-01 MX MX2019013034A patent/MX2019013034A/es unknown
- 2018-05-01 EP EP18793916.0A patent/EP3618866A4/fr active Pending
- 2018-05-01 SG SG11201910134S patent/SG11201910134SA/en unknown
- 2018-05-01 JP JP2019559826A patent/JP2020518598A/ja active Pending
- 2018-05-01 MA MA050501A patent/MA50501A/fr unknown
- 2018-05-01 US US16/609,671 patent/US20200262922A1/en active Pending
- 2018-05-01 BR BR112019022695-8A patent/BR112019022695A2/pt unknown
-
2019
- 2019-10-30 CL CL2019003143A patent/CL2019003143A1/es unknown
- 2019-10-30 CO CONC2019/0012143A patent/CO2019012143A2/es unknown
-
2023
- 2023-05-24 JP JP2023085581A patent/JP2023109942A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2019013034A (es) | 2020-02-05 |
BR112019022695A2 (pt) | 2020-05-26 |
EA201992526A1 (ru) | 2020-03-13 |
CN110678199A (zh) | 2020-01-10 |
EP3618866A1 (fr) | 2020-03-11 |
US20200262922A1 (en) | 2020-08-20 |
CO2019012143A2 (es) | 2020-01-17 |
EP3618866A4 (fr) | 2021-07-14 |
JP2023109942A (ja) | 2023-08-08 |
SG11201910134SA (en) | 2019-11-28 |
JP2020518598A (ja) | 2020-06-25 |
KR20190142393A (ko) | 2019-12-26 |
KR102624564B1 (ko) | 2024-01-12 |
CA3060695A1 (fr) | 2018-11-08 |
AU2018263837A1 (en) | 2019-12-05 |
CL2019003143A1 (es) | 2020-03-20 |
TN2019000294A1 (en) | 2021-05-07 |
WO2018204343A1 (fr) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50501A (fr) | Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation | |
MA50661A (fr) | Formulations stables d'anticorps anti-tigit seuls et en association avec des anticorps du récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation | |
MA50663A (fr) | Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA45595A (fr) | Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation | |
MA52781A (fr) | Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA44783A (fr) | Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4 | |
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA47691A (fr) | Anticorps anti-cd33 et leurs procédés d'utilisation | |
MA45671A (fr) | Anticorps antivirus zika et procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
MA43053A (fr) | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation | |
MA48462A (fr) | Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation | |
MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation |